New Nanovaccine Shows Promise in Fighting Cancer
Scientists have developed a novel vaccine strategy using hybrid membrane-coated nanoparticles to provoke robust immune responses against cancer. Led by Profs. NIE Guangjun, WU Yan, and ZHAO Yuliang, the team aims to stimulate patients' immune systems to specifically target and kill tumor cells.
The research team, with a history of developing nano-based strategies for anti-tumor immunotherapy, has created a unique vaccine that combines tumor membrane antigens and bacterial inner membrane on polymer nanoparticles. This hybrid membrane nanovaccine activates dendritic cells (DCs) and T cells, provoking both innate and adaptive immune responses.
In mouse tumor models, the vaccine demonstrated promising results. It prevented tumor recurrence, prolonged survival, and provided long-term protection against tumor rechallenge. This breakthrough could significantly impact postoperative treatment and prevention of metastasis.
The novel hybrid membrane nanovaccine, developed by Profs. NIE Guangjun, WU Yan, and ZHAO Yuliang, shows great potential in stimulating robust immune responses against cancer. Its success in mouse models suggests it could be a game-changer in preventing tumor recurrence and providing long-term protection against cancer.
Read also:
- Rosselkhozbank's Yakutsk Branch Expands 'Farmer School' to Train SVO Veterans in Agribusiness
- Emerging Fashions in Marijuana Storage: TVLPK's Attractive Gear for Cannabis Carrying
- The Distinction Between Sexual Identity and Gender Identity
- Symptoms, Prevention Strategies, and Management Methods for Measles
